摘要
在六个月的开放性研究中发现对阿尔茨海默症患者静脉注射免疫球蛋白可以对其认知有益。其中一项研究表明这些含有少量抗体的制剂直接对抗单体和寡聚Aβ是其对患者治疗的有效基础。为了检验这一假设,我们将Gammagard®,静脉注射免疫球蛋白( IVIG)的一个版本,注入已存在淀粉样蛋白沉积物的淀粉样蛋白前体蛋白(APP)转基因小鼠侧脑室,对小鼠注射超过4周,并在最后两周的治疗进行行为学测试,对大脑进行组织病理学分析。我们发现人类免疫球蛋白G(h-IgG)染色广泛分布在小鼠前脑,包括大脑皮质和海马,有些皮层神经元出现了集中的h-IgG抗体,但是我们并没有检测到有h-IgG标记的淀粉样蛋白斑的证据。IVIG治疗的小鼠的表型相比注射生理盐水的小鼠在活动、学习和记忆,或淀粉样蛋白沉积无明显变化,但注射抗Aβ单克隆抗体的 APP小鼠的淀粉样蛋白沉积确实有所减少。这些数据并不支持 IVIG制剂中的抗Aβ抗体对认知起作用的观点。
关键词: 行为测试,CD45,刚果红,小胶质细胞活化,旋臂水迷宫,疫苗接种
Current Alzheimer Research
Title:Intraventricular Human Immunoglobulin Distributes Extensively but Fails to Modify Amyloid in a Mouse Model of Amyloid Deposition
Volume: 11 Issue: 7
Author(s): Aurelie Joly-Amado, Milene Brownlow, Jacob Pierce, Advaitaa Ravipati, Erin Showalter, Qingyou Li, Marcia N Gordon and Dave Morga
Affiliation:
关键词: 行为测试,CD45,刚果红,小胶质细胞活化,旋臂水迷宫,疫苗接种
摘要: Intravenous immunoglobulin infusions into Alzheimer patients have been found to provide cognitive benefit over a period of 6 mo in open label studies. One suggestion has been that these preparations contain small amounts of antibodies directed against monomeric and oligomeric Aβ which underlie their effectiveness in patients. To test this hypothesis, we infused Gammagard®, a version of intravenous immunoglobulin (IVIG), into the lateral ventricle of amyloid precursor protein (APP) transgenic mice with pre-existing amyloid deposits. Mice were infused over 4 weeks, and tested behaviorally for the last 2 weeks of treatment. Brains were analyzed for histopathology. We found widespread distribution of human–immunoglobulin G (h-IgG) staining in the mouse forebrain, including cerebral cortices and hippocampus. Some cortical neurons appeared to concentrate the h-IgG, but we did not detect evidence of amyloid plaque labeling by h-IgG. The IVIG-treated mice had no change in phenotype compared to saline-infused animals with respect to activity, learning and memory, or amyloid deposition. APP mice infused with an anti-Aβ monoclonal antibody did show some reduction in amyloid deposits. These data do not support the argument that anti-Aβ antibodies in IVIG preparations are responsible for cognitive benefits seen with these preparations.
Export Options
About this article
Cite this article as:
Aurelie Joly-Amado, Milene Brownlow, Jacob Pierce, Advaitaa Ravipati, Erin Showalter, Qingyou Li, Marcia N Gordon and Dave Morga , Intraventricular Human Immunoglobulin Distributes Extensively but Fails to Modify Amyloid in a Mouse Model of Amyloid Deposition, Current Alzheimer Research 2014; 11 (7) . https://dx.doi.org/10.2174/1567205011666140812114341
DOI https://dx.doi.org/10.2174/1567205011666140812114341 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Extracellular HSP90: An Emerging Target for Cancer Therapy
Current Signal Transduction Therapy Cancer and Phase II Drug-Metabolizing Enzymes
Current Drug Metabolism Development of Meat and Poultry Products Enriched with n-3 PUFAs and their Functional Role
Current Nutrition & Food Science PET Studies of Brain Monoamine Transporters
Current Pharmaceutical Design Oxidative Stress in the Hypothalamus: the Importance of Calcium Signaling and Mitochondrial ROS in Body Weight Regulation
Current Neuropharmacology Simultaneous Liquid Chromatographic Determination of Selected Tricyclic Antidepressants and Co-Administered Benzodiazepines
Current Analytical Chemistry Protective Effects of Polydatin Against Dementia-Related Disorders
Current Neuropharmacology Hyper-Coagulable Profile with Elevated Pro-Thrombotic Biomarkers and Increased Cerebro- and Cardio-Vascular Disease Risk Exist Among Healthy Dyslipidemic Women
Current Neurovascular Research Identification of Disease-Relevant Genes for Molecularly-Targeted Drug Discovery
Current Cancer Drug Targets Dysfunction in Brain-Derived Neurotrophic Factor Signaling Pathway and Susceptibility to Schizophrenia, Parkinson’s and Alzheimer’s Diseases
Current Gene Therapy Anti-Seizure Medications and Estradiol for Neuroprotection in Epilepsy: The 2013 Update
Recent Patents on CNS Drug Discovery (Discontinued) Regional Grey Matter Loss and Brain Disconnection Across Alzheimer Disease Evolution
Current Medicinal Chemistry Pipeline Pharmacogenetics: A Novel Approach to Integrating Pharmacogenetics into Drug Development
Current Pharmaceutical Design Risk Factors for Myocardial Infarction in Women and Men: A Review of the Current Literature
Current Pharmaceutical Design Isolation of Secreted microRNAs (miRNAs) from Cell-conditioned Media
MicroRNA An fMRI Stroop Task Study of Prefrontal Cortical Function in Normal Aging, Mild Cognitive Impairment, and Alzheimers Disease
Current Alzheimer Research Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance
Current Medicinal Chemistry Action Mechanism of Antihistamines and the New Antihistamines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents High Throughput Sonication: Evaluation for Compound Solubilization
Combinatorial Chemistry & High Throughput Screening Targeting Functional Biomarkers in Schizophrenia with Neuroimaging
Current Pharmaceutical Design